← Back to Home

Lung-Protective Protein Rises Above Threshold in 4 People After One Infusion: Early Human Data Reported for SERP-01 Base Editing

Serapha’s four-person study offers preliminary evidence of gene correction through blood protein levels, functional tests, and a liver biopsy. But higher protein levels remain a long way from proving that the treatment can slow lung or liver disease.

By SURL BioNews

For patients with alpha-1 antitrypsin deficiency, a protein produced by the liver helps determine whether the lungs can withstand years of enzyme-related damage. Correcting the disease-causing gene so that the body can resume supplying functional protein could offer a way to intervene at the source of the disease. Early human data for SERP-01, announced by Serapha Bio on October 26, provide preliminary support for this concept: after a single infusion, blood levels of alpha-1 antitrypsin (AAT) in all four participants rose above the protective threshold used in the study.

This investigator-initiated study enrolled four patients with the PiZZ genotype. According to information released by Serapha through GlobeNewswire and republished by BioSpace, as of October 15, one participant had received 35 mg and three had received 45 mg of SERP-01, and total AAT concentrations in all four exceeded 11 µM. In the 45 mg group, total AAT reached or approached 20 µM, the lower limit of the normal range, during follow-up of up to 10 months; however, follow-up duration differed among participants.

AAT is produced primarily by the liver and inhibits neutrophil elastase, which damages lung tissue. In patients with PiZZ, the abnormal protein may accumulate in the liver, leaving the lungs insufficiently protected and posing a risk of liver damage. SERP-01 uses lipid nanoparticles to deliver base-editing tools designed to correct the disease-causing variant in the SERPINA1 gene and restore functional protein production. This is also why the study examined both protein concentrations and function.

Functional testing provided evidence beyond protein concentrations. The company said that in elastase inhibition assays at one and two months after infusion, serum activity in three participants approached that of pooled serum from healthy donors, while all four showed activity above that of PiZZ control serum. These results support the ability of the increased AAT to inhibit the enzyme, but serum activity in laboratory tests cannot yet directly establish whether patients’ lung function has improved or disease progression has slowed.

Another piece of evidence came from a liver biopsy in the participant who received 35 mg. DNA sequencing of the sample collected at week 10 after treatment showed 54% correction at the target site, with no unintended bystander editing detected at neighboring bases. This result comes from a single patient at a single time point; the absence of abnormalities at neighboring positions also does not establish that there is no off-target editing elsewhere in the genome or that long-term risks have been ruled out.

Regarding safety, as of the data cutoff, the company had reported no serious adverse events and had observed no treatment-related adverse events of grade 3 or higher. However, a sample of four people is insufficient to identify rare risks, and follow-up of up to 10 months is still too short to capture the long-term effects of gene editing. GlobeNewswire and BioSpace published the same company press release and cannot be considered two independent validations.

Serapha plans to initiate a Phase 2/3 trial in the United States in late 2026 or early 2027. Beyond confirming how long the increase in AAT can be maintained, the next step requires larger studies with longer follow-up to determine whether these biomarker changes can translate into actual benefits for the lungs and liver. The current data provide human evidence for the concept of a single treatment, but remain insufficient to prove that the course of the disease has been changed.

References

  1. Serapha Bio via GlobeNewswire
  2. Serapha Bio via BioSpace (press-release republication)